{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:07:19Z","timestamp":1762898839457},"reference-count":23,"publisher":"American Association for Cancer Research (AACR)","issue":"10","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Experimental and clinical data suggest that aspirin and other nonsteroidal inflammatory drugs may delay the progression of prostate cancer through inhibition of the COX pathway and its effects on cellular proliferation, apoptosis, and angiogenesis. Epidemiologic data support a reduced risk of prostate cancer incidence with aspirin use, yet no evidence exists about whether aspirin after diagnosis influences progression or survival. We conducted a prospective study of 3,986 participants of the Health Professionals Follow-up Study, with a prostate cancer diagnosis between January 1, 1990, and December 31, 2005. We used Cox proportional hazards regression to evaluate the association between aspirin use after diagnosis and the development of metastases or fatal prostate cancer through January 31, 2008, adjusting for risk factors associated with incidence and mortality in this cohort, prediagnostic aspirin use, Gleason score, tumor\u2013node\u2013metastasis (TNM) stage, and primary treatment. In total, 265 men developed bony or other organ metastases or fatal prostate cancer during the 18 years of follow-up. We observed no association between updated aspirin use after diagnosis and lethal prostate cancer [tablets\/week: &amp;lt;2: HR, 1.12; 95% confidence interval (CI), 0.72\u20131.72; 2\u20135: HR, 1.05; 95% CI, 0.62\u20131.80; \u2265 6: HR, 1.08; 95% CI, 0.76\u20131.54; Ptrend = 0.99]. The results remained unchanged when we examined aspirin use at baseline only (Ptrend = 0.70) or frequency of use (d\/wk; Ptrend = 0.35) or limited the outcome to fatal prostate cancer (Ptrend = 0.63). There was no association between aspirin use after a prostate cancer diagnosis and lethal disease in this cohort of prostate cancer survivors. Cancer Prev Res; 5(10); 1223\u20138. \u00a92012 AACR.<\/jats:p>","DOI":"10.1158\/1940-6207.capr-12-0171","type":"journal-article","created":{"date-parts":[[2012,9,8]],"date-time":"2012-09-08T05:41:25Z","timestamp":1347082885000},"page":"1223-1228","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Aspirin Use after a Prostate Cancer Diagnosis and Cancer Survival in a Prospective Cohort"],"prefix":"10.1158","volume":"5","author":[{"given":"Preet K.","family":"Dhillon","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 3Departments of Epidemiology & Biostatistics and Urology, University of California at San Francisco, San Francisco, California; and 4South Asia Network for Chronic Disease, Public Health Foundation of India, New Delhi, India"},{"name":"Authors' Affiliations:\u20081Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 3Departments of Epidemiology & Biostatistics and Urology, University of California at San Francisco, San Francisco, California; and 4South Asia Network for Chronic Disease, Public Health Foundation of India, New Delhi, India"},{"name":"Authors' Affiliations:\u20081Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 3Departments of Epidemiology & Biostatistics and Urology, University of California at San Francisco, San Francisco, California; and 4South Asia Network for Chronic Disease, Public Health Foundation of India, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey A.","family":"Kenfield","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 3Departments of Epidemiology & Biostatistics and Urology, University of California at San Francisco, San Francisco, California; and 4South Asia Network for Chronic Disease, Public Health Foundation of India, New Delhi, India"},{"name":"Authors' Affiliations:\u20081Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 3Departments of Epidemiology & Biostatistics and Urology, University of California at San Francisco, San Francisco, California; and 4South Asia Network for Chronic Disease, Public Health Foundation of India, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir J.","family":"Stampfer","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 3Departments of Epidemiology & Biostatistics and Urology, University of California at San Francisco, San Francisco, California; and 4South Asia Network for Chronic Disease, Public Health Foundation of India, New Delhi, India"},{"name":"Authors' Affiliations:\u20081Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 3Departments of Epidemiology & Biostatistics and Urology, University of California at San Francisco, San Francisco, California; and 4South Asia Network for Chronic Disease, Public Health Foundation of India, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward L.","family":"Giovannucci","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 3Departments of Epidemiology & Biostatistics and Urology, University of California at San Francisco, San Francisco, California; and 4South Asia Network for Chronic Disease, Public Health Foundation of India, New Delhi, India"},{"name":"Authors' Affiliations:\u20081Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 3Departments of Epidemiology & Biostatistics and Urology, University of California at San Francisco, San Francisco, California; and 4South Asia Network for Chronic Disease, Public Health Foundation of India, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June M.","family":"Chan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 3Departments of Epidemiology & Biostatistics and Urology, University of California at San Francisco, San Francisco, California; and 4South Asia Network for Chronic Disease, Public Health Foundation of India, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2012,10,4]]},"reference":[{"key":"2022060816085776200_bib1","first-page":"1483","article-title":"A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer","volume":"29","author":"Sooriakumaran","year":"2009","journal-title":"Anticancer Res"},{"key":"2022060816085776200_bib2","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1200\/JCO.2009.21.9410","article-title":"Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers","volume":"27","author":"Antonarakis","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060816085776200_bib3","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1200\/JCO.2005.03.7804","article-title":"Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and\/or radiation therapy","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"2022060816085776200_bib4","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1158\/1078-0432.CCR-05-2067","article-title":"Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy","volume":"12","author":"Pruthi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022060816085776200_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1748-717X-1-9","article-title":"Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study","volume":"1","author":"Ganswindt","year":"2006","journal-title":"Radiat Oncol"},{"key":"2022060816085776200_bib6","first-page":"93","article-title":"A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer","volume":"6","author":"Sooriakumaran","year":"2009","journal-title":"Cancer Genomics Proteomics"},{"key":"2022060816085776200_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ijc.23481","article-title":"A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor","volume":"123","author":"Cai","year":"2008","journal-title":"Int J Cancer"},{"key":"2022060816085776200_bib8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","article-title":"Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement","volume":"10","author":"Cuzick","year":"2009","journal-title":"Lancet Oncol"},{"key":"2022060816085776200_bib9","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"2022060816085776200_bib10","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1002\/ijc.25811","article-title":"Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988\u20132006","volume":"128","author":"Dhillon","year":"2011","journal-title":"Int J Cancer"},{"key":"2022060816085776200_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.bjc.6601416","article-title":"Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis","volume":"90","author":"Mahmud","year":"2004","journal-title":"Br J Cancer"},{"key":"2022060816085776200_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2407-3-28","article-title":"Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis","volume":"3","author":"Gonzalez-Perez","year":"2003","journal-title":"BMC Cancer"},{"key":"2022060816085776200_bib13","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/oxfordjournals.aje.a116211","article-title":"Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals","volume":"135","author":"Rimm","year":"1992","journal-title":"Am J Epidemiol"},{"key":"2022060816085776200_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/pros.2990210521","article-title":"The TNM classification of prostate cancer","volume":"4","author":"Schroder","year":"1992","journal-title":"Prostate Suppl"},{"key":"2022060816085776200_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/oxfordjournals.aje.a113804","article-title":"Test of the National Death Index","volume":"119","author":"Stampfer","year":"1984","journal-title":"Am J Epidemiol"},{"key":"2022060816085776200_bib16","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/ijc.22788","article-title":"Risk factors for prostate cancer incidence and progression in the health professionals follow-up study","volume":"121","author":"Giovannucci","year":"2007","journal-title":"Int J Cancer"},{"key":"2022060816085776200_bib17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnci\/dji173","article-title":"A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence","volume":"97","author":"Jacobs","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2022060816085776200_bib18","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jnci\/djk132","article-title":"A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence","volume":"99","author":"Jacobs","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2022060816085776200_bib19","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1158\/0008-5472.CAN-08-0107","article-title":"The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth","volume":"68","author":"Jin","year":"2008","journal-title":"Cancer Res"},{"key":"2022060816085776200_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2008.10.053","article-title":"Suppression of Wnt\/beta-catenin signaling inhibits prostate cancer cell proliferation","volume":"602","author":"Lu","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"2022060816085776200_bib21","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1056\/NEJMc0706698","article-title":"Aspirin and hormone therapy for prostate cancer","volume":"357","author":"D'Amico","year":"2007","journal-title":"N Engl J Med"},{"key":"2022060816085776200_bib22","first-page":"571","article-title":"Presence of prostate cells in bone marrow biopsies as a sign of micrometastasis in cancer patients","volume":"21","author":"Murray","year":"2009","journal-title":"Oncol Rep"},{"key":"2022060816085776200_bib23","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1002\/1097-0142(19941101)74:9<2533::AID-CNCR2820740922>3.0.CO;2-D","article-title":"Identification of bone marrow micrometastases in patients with prostate cancer","volume":"74","author":"Wood","year":"1994","journal-title":"Cancer"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/5\/10\/1223\/2250576\/1223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/5\/10\/1223\/2250576\/1223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T17:45:05Z","timestamp":1654710305000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/5\/10\/1223\/49917\/Aspirin-Use-after-a-Prostate-Cancer-Diagnosis-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,1]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,10,4]]},"published-print":{"date-parts":[[2012,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-12-0171","relation":{},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,1]]}}}